natgillin/translations-raw huggingface dataset:
► Check the label to make sure it is the right type of insulin. 
Provjerite naljepnicu kako biste bili sigurni da je vrsta inzulina odgovarajuća.
You must use the pen as described in the Instructions on how to use Mixtard 30 FlexPen. 
Brizgalicom morate rukovati na način opisan u uputama za uporabu Mixtard 30 FlexPen brizgalice.
After removing Mixtard vial, cartridge or pre-filled pen from the refrigerator, it is recommended to allow the Mixtard vial, cartridge or pre-filled pen to reach room temperature before resuspending the insulin as instructed for first time use. 
6.6 Posebne mjere za zbrinjavanje i druga rukovanja lijekom Nakon što se izvadi iz hladnjaka, preporučuje se pustiti Mixtard bočicu, uložak ili napunjenu brizgalicu da dosegne sobnu temperaturu prije resuspendiranja inzulina prema uputama za prvu uporabu.
Mixtard vials are for use with insulin syringes with a corresponding unit scale. 
Mixtard bočice koriste se s inzulinskim štrcaljkama s odgovarajućom jediničnom skalom.
► After each injection, be sure to remove and discard the needle and store Mixtard without the needle attached. 
► Nakon svakog injiciranja iglu obavezno skinite i bacite u otpad te spremite Mixtard bez pričvršćene igle.
Mixtard 30 vial (40 international units/ml)/Mixtard 30 vial (100 international units/ml) 
Mixtard 30 bočica (40 internacionalnih jedinica/ml)/Mixtard 30 bočica (100 internacionalnih jedinica/ml)
Mixtard is a mixture consisting of 40% soluble human insulin and 60% isophane human insulin. 
Mixtard je mješavina koja se sastoji od 40% otopine humanog inzulina i 60% humanog izofan inzulina.
What Mixtard is and what it is used for What you need to know before you use Mixtard How to use Mixtard 
Što morate znati prije nego počnete primjenjivati Mixtard Kako primjenjivati Mixtard
Read carefully the Instructions on how to use Mixtard 30 InnoLet included in this package leaflet. 
Pažljivo pročitajte upute za uporabu Mixtard 30 InnoLet brizgalice u ovoj Uputi o lijeku.
Mixtard is a mixture consisting of 50% soluble human insulin and 50% isophane human insulin. 
Mixtard je mješavina koja se sastoji od 50% otopine humanog inzulina i 50% humanog izofan inzulina.
Mixtard 30 vial (40 international units/ml) 
Mixtard 30 bočica (40 internacionalnih jedinica/ml)
How to inject Mixtard 
Kako injicirati Mixtard
Mixtard is a mixture consisting of 30% soluble human insulin and 70% isophane human insulin. 
Mixtard je mješavina koja se sastoji od 30% otopine humanog inzulina i 70% humanog izofan inzulina.
Mixtard 30 vial (100 international units/ml) 
Mixtard 30 bočica (100 internacionalnih jedinica/ml)
► Needles and Mixtard InnoLet must not be shared. 
► Igle i Mixtard InnoLet ne smiju se dijeliti s drugim osobama.
Paediatric population Mixtard can be used in children and adolescents. 
Primjena u djece i adolescenata Mixtard se može primjenjivati u djece i adolescenata.
Read carefully the Instructions on how to use Mixtard 30 FlexPen included in this package leaflet. 
Pažljivo pročitajte upute za uporabu Mixtard 30 FlexPen brizgalice u ovoj Uputi o lijeku.
Mixtard InnoLet is only suitable for subcutaneous injections. 
Mixtard InnoLet je prikladan samo za potkožne injekcije.
► Needles and Mixtard FlexPen must not be shared. 
► Igle i Mixtard FlexPen ne smiju se dijeliti s drugim osobama.
Mixtard FlexPen is only suitable for subcutaneous injections. 
Mixtard FlexPen je prikladan samo za potkožne injekcije.
How to handle Mixtard 30 FlexPen 
Kako rukovati brizgalicom Mixtard 30 FlexPen
Mixtard Penfill is only suitable for subcutaneous injections from a reusable pen. 
Mixtard Penfill je prikladan samo za potkožne injekcije iz brizgalice za višekratnu uporabu.
► Mixtard FlexPen is only suitable for injecting under the skin. 
► Mixtard FlexPen je prikladan samo za ubrizgavanje pod kožu.
How to take Mixtard 
Kako primijeniti Mixtard
Mixtard FlexPen is only suitable for injecting under the skin. 
Mixtard FlexPen je prikladan samo za ubrizgavanje pod kožu.
► Mixtard InnoLet is only suitable for injecting under the skin. 
► Mixtard InnoLet je prikladan samo za ubrizgavanje pod kožu.
Mixtard InnoLet is only suitable for injecting under the skin. 
Mixtard InnoLet je prikladan samo za ubrizgavanje pod kožu.
► Mixtard Penfill is only suitable for injecting under the skin using a reusable pen. 
► Mixtard Penfill je prikladan samo za ubrizgavanje pod kožu pomoću brizgalice za višekratnu uporabu.
► Needles and Mixtard Penfill must not be shared. 
► Igle i Mixtard Penfill ne smiju se dijeliti s drugim osobama.
Before using Mixtard 
Prije primjene lijeka Mixtard
Mixtard Penfill is only suitable for injecting under the skin using a reusable pen. 
Mixtard Penfill je prikladan samo za ubrizgavanje pod kožu pomoću brizgalice za višekratnu uporabu.
Each prefilled pen contains 300 IU of human insulin in 3 ml suspension for injection. 
Jedna napunjena brizgalica sadrži 300 IU humanog inzulina u 3 ml suspenzije za injekciju.
Contents of the pack and other information What Mixtard 50 contains 
Sadržaj pakiranja i druge informacije Što Mixtard 50 sadrži - Djelatna tvar je humani inzulin.
Mixtard FlexPen is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm. FlexPen delivers 1-60 units in increments of 1 unit. 
Mixtard FlexPen je napunjena brizgalica namijenjena uporabi s jednokratnim iglama NovoFine ili NovoTwist duljine do 8 mm.
Contents of the pack and other information What Mixtard 40 contains 
Sadržaj pakiranja i druge informacije Što Mixtard 40 sadrži - Djelatna tvar je humani inzulin.
Contents of the pack and other information What Mixtard 30 contains 
Sadržaj pakiranja i druge informacije Što Mixtard 30 sadrži - Djelatna tvar je humani inzulin.
Preparing your Mixtard 30 FlexPen 
Priprema Mixtard 30 FlexPen brizgalice
Needles and Mixtard Penfill must not be shared. 
Igle i Mixtard Penfill ne smiju se dijeliti s drugim osobama.
Mixtard 30 40 IU/ml Suspension for injection Insulin human 
Mixtard 30 40 IU/ml Suspenzija za injekciju humani inzulin
How to store Mixtard 
Kako primjenjivati Mixtard
Mixtard InnoLet is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm. InnoLet delivers 1-50 units in increments of 1 unit. 
Mixtard InnoLet je napunjena brizgalica namijenjena uporabi s jednokratnim iglama NovoFine ili NovoTwist duljine do 8 mm.
Mixtard 30 FlexPen 100 international units/ml suspension for injection in pre-filled pen. 
Mixtard 30 FlexPen 100 internacionalnih jedinica/ml suspenzija za injekciju u napunjenoj brizgalici.
Mixtard 30 100 IU/ml Suspension for injection Insulin human 
Mixtard 30 100 IU/ml Suspenzija za injekciju humani inzulin
Mixtard 30 vial, Penfill and FlexPen: 
Mixtard 30 bočica, Penfill i FlexPen: Novo Nordisk A/S
Mixtard 30 40 international units/ml suspension for injection in vial. 
Mixtard 30 40 internacionalnih jedinica/ml suspenzija za injekciju u bočici.
Mixtard 50 Penfill 100 international units/ml suspension for injection in cartridge. 
Mixtard 50 Penfill 100 internacionalnih jedinica/ml suspenzija za injekciju u ulošku.
Mixtard 30 InnoLet EU/1/02/231/030 EU/1/02/231/031 EU/1/02/231/032 
EU/1/02/231/030 EU/1/02/231/031 EU/1/02/231/032
EU/1/02/231/003 1 vial of 10 ml EU/1/02/231/004 5 vials of 10 ml 
EU/1/02/231/004 5 bočica od 10 ml
Mixtard 30 InnoLet, Mixtard 40 and 50 Penfill: 
Nazivi i adrese proizvođača odgovornih za puštanje serije lijeka u promet Mixtard 30 InnoLet, Mixtard 40 i 50 Penfill:
Mixtard 50 contains less than 1 mmol sodium (23 mg) per dose, i.e. Mixtard 50 is essentially ‘sodiumfree'. 
Mixtard 50 sadrži manje od 1 mmol (23 mg) natrija po dozi tj.
Mixtard 40 Penfill 100 international units/ml suspension for injection in cartridge. 
Mixtard 40 Penfill 100 internacionalnih jedinica/ml suspenzija za injekciju u ulošku.
Mixtard 30 InnoLet 100 international units/ml suspension for injection in pre-filled pen. 
Mixtard 30 InnoLet 100 internacionalnih jedinica/ml suspenzija za injekciju u napunjenoj brizgalici.
EU/1/02/231/036 5 packs of 1 x 10 ml vial 
EU/1/02/231/016 10 uložaka od 3 ml
Mixtard 30 contains less than 1 mmol sodium (23 mg) per dose, i.e. Mixtard 30 is essentially ‘sodiumfree'. 
Mixtard 30 sadrži manje od 1 mmol (23 mg) natrija po dozi tj.
Mixtard 30 Penfill 100 international units/ml suspension for injection in cartridge. 
Mixtard 30 Penfill 100 internacionalnih jedinica/ml suspenzija za injekciju u ulošku.
Mixtard 30 FlexPen EU/1/02/231/033 EU/1/02/231/034 EU/1/02/231/035 
EU/1/02/231/033 EU/1/02/231/034 EU/1/02/231/035
Mixtard 30 FlexPen 100 IU/ml Suspension for injection Insulin human 
Mixtard 30 FlexPen 100 IU/ml Suspenzija za injekciju humani inzulin s.c.
Mixtard 30 100 international units/ml suspension for injection in vial. 
Mixtard 30 100 internacionalnih jedinica/ml suspenzija za injekciju u bočici.
Mixtard 40 contains less than 1 mmol sodium (23 mg) per dose, i.e. Mixtard 40 is essentially ‘sodiumfree'. 
Mixtard 40 sadrži manje od 1 mmol (23 mg) natrija po dozi tj.
Resuspension of Mixtard 
Miješanje lijeka Mixtard
Package leaflet: Information for the user Mixtard 30 40 IU/ml (international units/ml) suspension for injection in vial human insulin 
Uputa o lijeku: Informacije za korisnika Mixtard 30 40 IU/ml (internacionalnih jedinica/ml) suspenzija za injekciju u bočici humani inzulin
Mixtard 30 FlexPen 100 IU/ml Suspension for injection in pre-filled pen Insulin human 
Mixtard 30 FlexPen 100 IU/ml Suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Mixtard 30 40 IU/ml Suspension for injection Insulin human SC 
Mixtard 30 40 IU/ml Suspenzija za injekciju humani inzulin s.c.
Mixtard 30 100 IU/ml Suspension for injection Insulin human SC 
Mixtard 30 100 IU/ml Suspenzija za injekciju humani inzulin s.c.
Package leaflet: Information for the user Mixtard 50 Penfill 100 IU/ml (international units/ml) suspension for injection in cartridge human insulin 
Uputa o lijeku: Informacije za korisnika Mixtard 50 Penfill 100 IU/ml (internacionalnih jedinica/ml) suspenzija za injekciju u ulošku humani inzulin
Mixtard 30 Penfill 100 IU/ml Suspension for injection in cartridge Insulin human 
Mixtard 30 Penfill 100 IU/ml Suspenzija za injekciju u ulošku humani inzulin
Mixtard 40 Penfill 100 IU/ml Suspension for injection in cartridge Insulin human 
Mixtard 40 Penfill 100 IU/ml Suspenzija za injekciju u ulošku humani inzulin
Package leaflet: Information for the user Mixtard 30 100 IU/ml (international units/ml) suspension for injection in vial human insulin 
Uputa o lijeku: Informacije za korisnika Mixtard 30 100 IU/ml (internacionalnih jedinica/ml) suspenzija za injekciju u bočici humani inzulin
Package leaflet: Information for the user Mixtard 40 Penfill 100 IU/ml (international units/ml) suspension for injection in cartridge human insulin 
Uputa o lijeku: Informacije za korisnika Mixtard 40 Penfill 100 IU/ml (internacionalnih jedinica/ml) suspenzija za injekciju u ulošku humani inzulin
Package leaflet: Information for the user Mixtard 30 FlexPen 100 IU/ml (international units/ml) suspension for injection in pre-filled pen human insulin 
Uputa o lijeku: Informacije za korisnika Mixtard 30 FlexPen 100 IU/ml (internacionalnih jedinica/ml) suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Mixtard contains less than 1 mmol sodium (23 mg) per dose, i.e. Mixtard is essentially ‘sodium-free'. 
Mixtard sadrži natrij Mixtard sadrži manje od 1 mmol (23 mg) natrija po dozi, tj.
Mixtard 30 vial (40 international units/ml)/Mixtard 30 vial (100 international units/ml) Vial (type 1 glass) closed with a disc (bromobutyl/polyisoprene rubber) and a protective tamper-proof plastic cap containing 10 ml of suspension. 
Mixtard 30 bočica (100 internacionalnih jedinica/ml) 1 bočica sadrži 10 ml što odgovara 1000 internacionalnih jedinica.
Mixtard 30 InnoLet 100 IU/ml Suspension for injection in pre-filled pen Insulin human 
Mixtard 30 InnoLet 100 IU/ml Suspenzija za injekciju u napunjenoj brizgalici humani inzulin
EU/1/02/231/033 1 pen of 3 ml EU/1/02/231/034 5 pens of 3 ml EU/1/02/231/035 10 pens of 3 ml 
EU/1/02/231/034 5 brizgalica od 3 ml
Package leaflet: Information for the user Mixtard 30 Penfill 100 IU/ml (international units/ml) suspension for injection in cartridge human insulin 
Uputa o lijeku: Informacije za korisnika Mixtard 30 Penfill 100 IU/ml (internacionalnih jedinica/ml) suspenzija za injekciju u ulošku humani inzulin
Package leaflet: Information for the user Mixtard 30 InnoLet 100 IU/ml (international units/ml) suspension for injection in pre-filled pen human insulin 
Uputa o lijeku: Informacije za korisnika Mixtard 30 InnoLet 100 IU/ml (internacionalnih jedinica/ml) suspenzija za injekciju u napunjenoj brizgalici humani inzulin
EU/1/02/231/037 5 packs of 1 x 10 ml vial 
EU/1/02/231/018 5 uložaka od 3 ml
Mixtard 40 Penfill 100 IU/ml Suspension for injection Insulin human 
Mixtard 40 Penfill 100 IU/ml Suspenzija za injekciju humani inzulin s.c.
EU/1/02/231/001 1 vial of 10 ml EU/1/02/231/002 5 vials of 10 ml 
EU/1/02/231/002 5 bočica od 5 ml
Mixtard 30 InnoLet 100 IU/ml Suspension for injection Insulin human 
Mixtard 30 InnoLet 100 IU/ml Suspenzija za injekciju humani inzulin s.c.
Mixtard 30 Penfill 100 IU/ml Suspension for injection Insulin human 
Mixtard 30 Penfill 100 IU/ml Suspenzija za injekciju humani inzulin s.c.
Pharmacotherapeutic group: Drugs used in diabetes. 
Pioglitazon (tablete za liječenje šećerne bolesti tipa 2)
EU/1/02/231/011 1 cartridge of 3 ml EU/1/02/231/012 5 cartridges of 3 ml EU/1/02/231/013 10 cartridges of 3 ml 
EU/1/02/231/013 10 uložaka od 3 ml
EU/1/02/231/030 1 pen of 3 ml EU/1/02/231/031 5 pens of 3 ml EU/1/02/231/032 10 pens of 3 ml 
EU/1/02/231/032 10 brizgalica od 3 ml
EU/1/02/231/017 1 cartridge of 3 ml EU/1/02/231/018 5 cartridges of 3 ml EU/1/02/231/019 10 cartridges of 3 ml 
EU/1/02/231/019 10 uložaka od 3 ml
Doses are adjusted as necessary. 
Doze se prilagođavaju prema potrebi.
Metformin has been available in the EU since the 1950s. 
Metformin je dostupan u EU-u od 1950-ih godina.
This summary was last updated in 02-2017. 
Ovaj sažetak je posljednji put ažuriran u 02. 2017.
The full EPAR and risk management plan summary for Synjardy can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjeloviti EPAR za lijek Synjardy, kao i plan upravljanja rizikom, nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What is Synjardy and what is it used for? 
Što je Synjardy i za što se koristi?
In addition, the results indicated that the combination was associated with a beneficial decrease in body weight and blood pressure. 
Nadalje, rezultati ukazuju na to da je ta kombinacija povezana s korisnim snižavanjem tjelesne težine i krvnog tlaka.
Why is Synjardy approved? 
Zašto je Synjardy odobren?
This leads to a high level of glucose in the blood. 
To dovodi do visoke razine glukoze u krvi.
What measures are being taken to ensure the safe and effective use of Synjardy? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Synjardy?
The main measure of effectiveness was the occurrence of one of three major cardiovascular events: stroke, heart attack or death caused by cardiovascular disease. 
Glavna mjera djelotvornosti bila je prva pojava jednoga od tri glavna kardiovaskularna događaja: moždanog udara, srčanog udara ili smrti izazvane kardiovaskularnom bolešću.
• liver impairment, or problems with alcoholism or alcohol intoxication. 
• oštećenja jetre ili problema s alkoholizmom ili alkoholnom intoksikacijom.
Synjardy must not be used in patients with: 
Synjardy se ne smije koristiti kod bolesnika koji imaju:
This is a summary of the European public assessment report (EPAR) for Synjardy. 
Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Synjardy.
Similar benefits were seen in the studies regardless of the other diabetes medicines being taken. 
Slične su koristi uočene u ispitivanjima bez obzira na primjenu drugih lijekova protiv dijabetesa.
Empagliflozin has been authorised in the EU under the trade name Jardiance since 2014. 
Empagliflozin je odobren u EU-u pod zaštićenim imenom Jardiance od 2014. godine.
What are the risks associated with Synjardy? 
Koji su rizici povezani s lijekom Synjardy?
The European Commission granted a marketing authorisation valid throughout the European Union for Synjardy on 27 May 2015. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Synjardy na snazi u Europskoj uniji od 27. svibnja 2015.
Other information about Synjardy 
Ostale informacije o lijeku Synjardy
Some of these were continuations of the main studies that suggested the benefits of the combination continued with longer therapy. 
Dio tih ispitivanja bio je nastavak glavnih ispitivanja, što ukazuje na to da su se koristi te kombinacije nastavile s duljom terapijom.
The main measure of effectiveness was the reduction in the level of a substance in the blood called glycosylated haemoglobin (HbA1c) after 24 weeks of treatment. 
Glavna mjera djelotvornosti bilo je smanjenje količine tvari u krvi zvane glikozilirani hemoglobin (HbA1c) nakon 24 tjedna liječenja.
• in patients who are already taking metformin and empagliflozin as separate tablets. 
• u bolesnika koji već uzimaju metformin i empagliflozin kao zasebne tablete.
It is not intended to provide practical advice on how to use Synjardy. 
Svrha sažetka nije davati praktične savjete o primjeni lijeka Synjardy.
• severely reduced kidney function or conditions that could affect the kidneys such as dehydration, severe infection or a steep fall in blood pressure; 
• ozbiljno smanjenu funkciju bubrega ili stanja koja mogu utjecati na bubrege kao što su dehidracija, teška infekcija ili nagli pad krvnog tlaka;
Supportive evidence was provided from several further studies. 
Dokazi koji govore tome u prilog dostavljeni su iz nekoliko dodatnih ispitivanja.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Synjardy's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Synjardy nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
• metabolic acidosis (when the body produces more acid than it gets rid of) or diabetic pre-coma (dangerous complications of diabetes); 
• metaboličku acidozu (stanja pri kojem tijelo proizvodi više kiseline nego što je izlučuje) ili dijabetičku pretkomu (opasne komplikacije dijabetesa);
The recommended dose of Synjardy is one tablet twice a day with meals, and treatment is normally started with a tablet that supplies the dose of metformin the patient is already taking, together with the lowest dose (5 mg) of empagliflozin. 
Preporučena doza lijeka Synjardy je jedna tableta dva puta na dan uz obrok, a liječenje se najčešće započinje tabletom koja osigurava dozu metformina koju bolesnik već uzima, zajedno s najmanjom dozom empagliflozina (od 5 mg).
In those receiving empagliflozin, cardiovascular events occurred in 10.5% (490 out of 4,687) of patients compared with 12.1% (282 out of 2,333) of patients receiving placebo. 
Kod bolesnika koji su primali empagliflozin kardiovaskularni događaji nastupili su u 10,5 % (490 od 4 687) bolesnika u usporedbi s 12,1 % (282 od 2 333) bolesnika koji su primali placebo.
Synjardy is available as tablets containing 5 or 12.5 mg of empagliflozin with 850 or 1,000 mg of metformin, and can only be obtained with a prescription. 
Synjardy je dostupan u obliku tableta koje sadrže 5 ili 12,5 mg empagliflozina s 850 ili 1 000 mg metformina, a izdaje se samo na recept.
Overall, the additional reduction was 0.58 percentage points with a combination providing 5 mg of empagliflozin twice daily, and 0.62 percentage points with the 12.5 mg dose, and these reductions were considered clinically relevant. 
Ukupno gledajući, dodatno smanjenje iznosilo je 0,58 postotnih bodova u kombinaciji koja je osiguravala 5 mg empagliflozina dva puta dnevno i 0,62 postotna boda s dozom od 12,5 mg, a ta su smanjenja smatrana klinički relevantnima.
Among these, in patients who were also taking metformin (the other active substance in Synjardy), the three major cardiovascular events occurred in 9.9% (344 out of 3,459) of patients receiving empagliflozin and in 10.9% (189 out of 1,734) of patients receiving placebo. 
Među njima, u bolesnika koji su uzimali i metformin (drugu djelatnu tvar lijeka Synjardy), tri glavna kardiovaskularna događaja nastupila su u 9,9 % (344 od 3 459) bolesnika koji su primali empagliflozin i u 10,9 % (189 od 1 734) bolesnika koji su primali placebo.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Synjardy have been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Synjardy nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
The CHMP concluded that the medicine could help produce a clinically meaningful reduction in blood glucose in patients with type 2 diabetes, and the benefits and risks were in line with those of the individual active substances. 
CHMP je zaključio da lijek može pomoći u stvaranju klinički značajnog smanjenja razine glukoze u krvi u bolesnika s dijabetesom tipa 2 te su koristi i rizici bili u skladu s onima pojedinačno aktivnih tvari.
The benefits of empagliflozin in combination with metformin have been shown in 3 main studies involving 1,679 patients with type 2 diabetes whose blood sugar was not adequately controlled by metformin, alone or combined with other diabetes medicines (such as pioglitazone or a type of diabetes medicine called a sulphonylurea). 
Koristi empagliflozina u kombinaciji s metforminom utvrđene su u trima glavnim ispitivanjima kojima je obuhvaćeno 1 679 bolesnika s dijabetesom tipa 2 čije razine šećera u krvi nisu primjereno kontrolirane metforminom koji se uzima kao monoterapija ili u kombinaciji s drugim lijekovima protiv dijabetesa (poput pioglitazona ili vrste lijeka protiv dijabetesa naziva sulfonilureja).
If Synjardy is used in combination with insulin or a sulphonylurea (a medicine that increases the body's production of insulin), the doses of these medicines may need to be lowered to avoid hypoglycaemia (low blood sugar levels). 
Ako se Synjardy koristi u kombinaciji s inzulinom ili sulfonilurejom (lijekom koji povećava stvaranje inzulina u tijelu), doze tih lijekova možda će biti potrebno smanjiti kako bi se izbjegla hipoglikemija (niska razina šećera u krvi).
Synjardy is used: 
Lijek Synjardy primjenjuje se:
What benefits of Synjardy have been shown in studies? 
Koje su koristi lijeka Synjardy dokazane u ispitivanjima?
The study involved patients with type 2 diabetes who already had cardiovascular disease (such as angina, heart attack and stroke). 
U to su ispitivanje bili uključeni bolesnici s dijabetesom tipa 2 koji su već bolovali od kardiovaskularnih bolesti (npr. angina te srčani i moždani udar).
Metformin works mainly by reducing the production of glucose in the body and reducing its absorption from the gut. 
Metformin uglavnom djeluje tako da smanjuje stvaranje glukoze u tijelu i smanjuje njezinu apsorpciju iz crijeva.
• a condition that could reduce the supply of oxygen to body tissues (such as in patients with worsening heart failure, recent heart attack, breathing difficulty or a steep fall in blood pressure); 
• stanja koje može rezultirati smanjenom opskrbom tjelesnih tkiva kisikom (primjerice u bolesnika sa zatajenjem srca čije se stanje pogoršava, u bolesnika koji su nedavno imali srčani udar, u bolesnika s otežanim disanjem ili naglim padom krvnog tlaka);
Empagliflozin works by blocking a protein in the kidneys (called sodium-glucose co-transporter 2 or SGLT2). 
Empagliflozin djeluje blokiranjem proteina u bubrezima (naziva kotransporter 2 natrija i glukoze (SGLT2)).
• in patients whose diabetes is not sufficiently controlled by metformin alone; 
• u bolesnika kod kojih se ne može postići dovoljna kontrola dijabetesa samo metforminom;